Year: 2025

– Grew revenue from continuing operations 10% annually and 14% quarterly compared to the same period in 2023 – – Increased system-wide sales 9% for both the year and Q4 2024 – SCOTTSDALE, Ariz., March 13, 2025 (GLOBE NEWSWIRE) — The Joint Corp. (NASDAQ: JYNT), a national operator, manager, and franchisor of chiropractic clinics, reported its financial results for the quarter ended December 31, 2024. The results of operations of the corporate clinics business segment have been classified as discontinued operations for all periods presented, and the following figures represent continuing operations unless otherwise stated. Q4 2024 Financial HighlightsGrew revenue to $14.4 million, up 14% compared to Q4 2023. Reported net income from continuing operations of $986,000, compared to net loss from continuing operations...

Ongoing Phase 1 and Phase 2 clinical programs continue to exhibit long-term durable remissions in hard-to-treat cancers, including glioblastoma (GBM) and 100% of treated Acute Myeloid Leukemia (AML) patients remaining relapse-free Expanded pipeline with INB-600 platform, featuring novel gamma-delta T Cell engager (TCE) targeting CD19 for potential use in oncology and autoimmune diseases Continued operational execution with strengthened strategic focus on aligning resources in an effort to drive high-impact programs forward Maintaining cash position to support operations and achievement of anticipated development milestones throughout 2025 and into 2026NEW YORK, March 13, 2025 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today reported...

Fourth Quarter Comparable Sales Increased 5.9%Fourth Quarter Gross Margin Increased 190 Basis Points to 36.2%Fourth Quarter Earnings Per Share Improved to $0.78 from ($1.73)First Quarter-To-Date Comparable Sales up 4.3%, Led by North America Up 6.4%Board Approves New Stock Repurchase Authorization LYNNWOOD, Wash., March 13, 2025 (GLOBE NEWSWIRE) — Zumiez Inc. (NASDAQ: ZUMZ) a leading specialty retailer of apparel, footwear, equipment and accessories for young men and women, today reported results for the fourth quarter and year ended February 1, 2025. Net sales for the fourth quarter ended February 1, 2025 (13 weeks) decreased 0.9% to $279.2 million from $281.8 million in the fourth quarter ended February 3, 2024 (14 weeks). Comparable sales for the thirteen weeks ended February 1, 2025 increased 5.9%. Net income in the fourth...

— Robust Growth, Including Record Full Year Gross Margin, as Business Continues to Expand — CHINO, Calif., March 13, 2025 (GLOBE NEWSWIRE) — Karat Packaging Inc. (Nasdaq: KRT) (“Karat” or the “Company”), a specialty distributor and manufacturer of environmentally friendly, disposable foodservice products and related items, today announced financial results for its fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 HighlightsNet sales of $101.6 million, up 6.3 percent, from $95.6 million in the prior-year quarter. Gross profit of $39.8 million, up 16.8 percent, from $34.1 million in prior-year quarter. Gross margin of 39.2 percent versus 35.7 percent in the prior-year quarter. Net income of $5.9 million, up 40.3 percent, from $4.2 million in the prior-year quarter. Net income margin of 5.8 percent versus...

Net Revenue Increased 8.7% and 4.6% for the Fourth Quarter and Full Year 2024, Respectively Pre-Recorded Earnings Call Webcast Available on Investor Relations Website LAS VEGAS, March 13, 2025 (GLOBE NEWSWIRE) — HF Foods Group Inc. (NASDAQ: HFFG) (“HF Foods” or the “Company”), a leading food distributor to Asian restaurants across the United States, reported its unaudited financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial ResultsNet revenue increased 8.7% to $305.3 million compared to $280.9 million in the prior year period. Gross profit decreased 0.2% to $52.2 million compared to $52.3 million in the prior year period. Gross profit margin decreased to 17.1% from 18.6% in the prior year period. Net loss of $43.9 million, mainly due to goodwill impairment of $46.3 million,...

Q4 2024 revenue increased 24.6% over Q3 2024; Full-year 2024 revenue grew 97.8% year-over-year Strong growth in key commercial metrics, including prescriber base, fill rates, and patient enrollments Secured $14.3 million net proceeds in financings, ensuring Nasdaq compliance Presented compelling healthcare resource utilization data on GIMOTI at key gastroenterology conferences, including an award-winning study on GLP-1 users with diabetic gastroparesis at ACG 2024 Conference call and webcast to be held today at 4:30 p.m. ET SOLANA BEACH, Calif., March 13, 2025 (GLOBE NEWSWIRE) — Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders with an emphasis on GIMOTI®, today announced financial results for the fourth quarter and full year ended December 31, 2024,...

Momentum Builds Across Programs with Key Data Milestones Expected in 2025 Cemacabtagene Ansegedleucel (Cema-Cel): First-Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL)Ongoing Pivotal Phase 2 ALPHA3 Trial Advancing with Site Activation and Patient Enrollment Lymphodepletion Selection and Futility Analysis Anticipated Around Mid-2025 Primary EFS Data Expected Around YE 2026 with Potential BLA Submission in 2027ALLO-329 in Autoimmune Disease (AID)Secured Investigational New Drug (IND) FDA Clearance for the RESOLUTION Basket Trial in Rheumatology Trial Initiation Targeted for Mid-2025; Proof-of-Concept Data Expected Around YE 2025ALLO-316 in Renal Cell Carcinoma (RCC)Presented Positive Phase 1 Data Highlighting Meaningful Response Rates in Patients with Advanced Renal Cell Carcinoma and the Potential of the CD70 Dagger® Technology...